The democratic role of campaign journalism: partisan representation and public participation

Campaign journalism is a distinctive but under-researched form of editorialised news reporting that aims to influence politicians rather than inform voters. In this it diverges from liberal norms of social responsibility, but instead campaigning newspapers make claims to represent the interests or opinions of publics such as their readers or groups affected by the issue. This could be understood as democratically valid in relation to alternative models such as participatory or corporatist democracy. This essay examines journalists’ understanding of the identity and views of these publics, and how their professional norms are operationalised in their journalistic practice in relation to five case studies in the Scottish press. The campaigns are analysed in terms of four normative criteria associated with corporatist and participatory democracy: firstly, the extent to which subjective advocacy is combined with objectivity and accuracy; secondly, the extent to which civic society organisations are accorded access; thirdly, whether the disadvantage of resource-poor groups in society is compensated for; and finally, to what extent the mobilisation of public support for the campaigns aims to encourage an active citizenry

Scandinavian Higher Education Governance – Pursuing Similar Goals through Different Organizational Arrangements

Under embargo until: 2022-02-03The differences and similarities among the three Scandinavian countries, Denmark, Norway, and Sweden have been discussed by social scientists on several occasions. Focusing on higher education (HE) governance systems, this paper raises three questions. (1) What are the differences and similarities among the three countries? (2) How can the similarities and differences be explained? (3) Are the similarities strong enough to justify the common label of a Scandinavian model of HE governance? The three HE governance systems are briefly described and compared. They are then analyzed as, respectively, outcomes of partisan politics or politico-administrative regimes. The paper argues that similarities such as publicness, massive investments, and emphasis on access are best explained in terms of partisan politics, while the variation in governance arrangements can best be explained by path dependencies following choices made at critical junctures within similar politicoadministrative regimes.acceptedVersio

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Fragment-based Discovery of Modulators of the Aurora-A Kinase

Allosteric inhibition of kinases presents an innovative and potentially selective method of targeting these enzymes for bioactive small molecule development. Contrary to the orthosteric inhibition of highly conserved and defined binding sites, allosteric inhibitors are challenging to develop due to the shallow and flat nature of their binding pockets yet present a desirable target for medicinal chemistry. This thesis focuses on the development of allosteric Aurora-A inhibitors, exploiting standard medicinal chemistry techniques as well as implementing a development workflow that focuses exclusively on productively elaborated fragments from high-throughput microscale arrays. Chapter 1 gives an overview of Aurora-A kinase structure and function and introduces existing small molecule inhibitors in various stages of development, including allosteric inhibitors and those targeting the Aurora-A/TPX2 protein-protein interaction. Chapter 1 also outlines modern drug discovery practices and focuses on recent methods for the high-throughput and integrated discovery and development of biologically active small molecules. Chapter 2 describes the design and implementation of three microscale reaction arrays for the activity-directed elaboration of allosteric inhibitors of Aurora-A kinase. Two dirhodium(II) carbenoid reaction arrays were performed, totalling 504 reactions, followed by high-throughput LC-MS analysis of reaction array 1 and purification of productive reactions. The identification of improved bioactive compounds guided the design of the third reaction array, exploiting amide bond formations.Chapter 3 describes the development of a series of fragments based on known allosteric inhibitors of Aurora-A kinase through design and synthesis of a library of fragments. The SAR landscape was initially explored through generation and biological screening of a small library, which was then supplemented with an in silico docking campaign. The combined SAR and docking results were used to design further analogues of elaborated fragments for synthesis and biological screening. Overall, this medicinal chemistry strategy resulted in the expansion of the SAR for the fragment series and led to an increase in biological potency against Aurora-A kinase